Targets for Ibrutinib Beyond B Cell Malignancies

Ibrutinib (Imbruvica(™)) is an irreversible, potent inhibitor of Bruton's tyrosine kinase (BTK). Over the last few years, ibrutinib has developed from a promising drug candidate to being approved by FDA for the treatment of three B cell malignancies, a truly remarkable feat. Few, if any medicin...

Descripción completa

Detalles Bibliográficos
Autores principales: Berglöf, A., Hamasy, A., Meinke, S., Palma, M., Krstic, A., Månsson, R., Kimby, E., Österborg, A., Smith, C. I. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347933/
https://www.ncbi.nlm.nih.gov/pubmed/26111359
http://dx.doi.org/10.1111/sji.12333

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347933/
https://www.ncbi.nlm.nih.gov/pubmed/26111359
http://dx.doi.org/10.1111/sji.12333

Ejemplares similares